Table 1.
Baseline characteristics of female-to-male transsexual study participants
| Testosterone-naïve (n = 8) | Testosterone-treated (n = 7) | All | |
|---|---|---|---|
| Age (years) | 33·1 ± 3·0 | 40·5 ± 4·0 | 37·0 ± 3·0 |
| Years on testosterone | 0 | 4·2 ± 1·0 | |
| Dose of testosterone* (mg testosterone ester/week) | 66·0 ± 6·0 | 76·0 ± 7·0 | 70·7 ± 4·5 |
| Current smokers (%) | 5/8 (63%) | 3/7 (43%) | 8 (53·3%) |
| Prior ovariectomy (%) | 0/8 | 5/7 (71%) | 5/15 (33%) |
| Baseline BMD | |||
| Spine L2–L4 (gm/cm2) | 1·211 ± 0·06 | 1·134 ± 0·06 | 1·172 ± 0·04 |
| Femoral neck (gm/cm2) | 1·072 ± 0·07 | 0·861 ± 0·03 | 0·984 ± 0·05 |
Data expressed as mean ± SEM.
*
Subjects took either testosterone cypionate or enanthate.